Cancer Treatment

ABSTRACT

The present invention provides a method for the treatment of cancer with erdafitinib.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.16/483,579, filed Aug. 5, 2019, which is a national stage of PCTApplication No. PCT/EP2018/052694, filed Feb. 2, 2018, which claimspriority to U.S. Patent Application No. 62/455,211, filed Feb. 6, 2017and to EPO Patent Application No. 17209098.7, filed Dec. 20, 2017, allof which are hereby incorporated by reference in their entirety.

The present invention provides for the treatment of cancer witherdafitinib with a high potential for response while limiting potentialtoxicities such as for example nail toxicities.

The present invention provides for treatment of cancer with erdafitinibthat maximizes erdafitinib exposure while limiting potential toxicities.

The present invention provides for treatment of cancer with erdafitinibwith a high objective response rate, in particular with an objectiveresponse rate of at least 40%, in particular with an objective responserate of at least 40% in chemo-naïve cancer patients, with an objectiveresponse rate of at least 40% in cancer patients who had diseaseprogression after one prior line of chemotherapy, with an objectiveresponse rate of at least 40% in cancer patients who had diseaseprogression after two or more prior lines of chemotherapy.

The present invention provides for treatment of cancer with erdafitinibwith a short time to response, in particular with a median time toresponse less than 2 months.

DESCRIPTION OF THE FIGURES

FIG. 1 represents the study scheme for the Phase 2, multicenter,open-label study to evaluate the efficacy and safety of erdafitinib insubjects with metastatic or surgically unresectable urothelial cancerharboring selected FGFR (fibroblast growth factor receptor) geneticalterations (FGFR translocations or mutations).

FIG. 2 represents a Waterfall plot of maximum percentage reduction frombaseline in sum of target lesion diameters among patients treated withthe regimen of 8 mg continuous erdafitinib (Regimen 3 of the phase 2study (FIG. 1)). M, FGFR mutation; T, FGFR translocation.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides for the treatment of cancer witherdafitinib that maximizes erdafitinib exposure already within the firstcycle of treatment (set at, for example, the first 28 days of treatmentor the first 21 days of treatment, in particular with daily continuousdosing) as well as during further treatment cycles (set at, for example,28 days/cycle or 21 days/cycle, in particular with daily continuousdosing) while limiting potential toxicities.

The present invention provides for treatment of cancer with erdafitinibthat maximizes erdafitinib exposure and brings the subject in need oferdafitinib quickly at the target serum phosphate range, in particularranging from and including 5.5 mg/dL to <7 mg/dL or ranging from andincluding 5.5 mg/dL to ≤9 mg/dL, to keep phosphate based toxicitiesunder control.

Erdafitinib orN-(3,5-dimethoxyphenyl)-N-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamineis a pan-fibroblast growth factor receptor (FGFR 1,2,3,4) tyrosinekinase inhibitor.

The chemical structure of erdafitinib is

Serum phosphate levels may represent an on-target pharmacodynamic markerpointing towards FGFR target engagement by erdafitinib. Levels of serumphosphate are likely to increase with target engagement. But the serumphosphate levels need to be monitored to minimize or avoid or controlacute and prolonged hyperphosphatemia.

It has been found that a higher proportion of patients are responding toerdafitinib treatment when serum phosphate levels are ≥5.5 mg/dL.

In an embodiment, the proportion of patients showing objective responserate is, depending on the cancer type, at least 15%, or 20%, or 25%, or30%, or 35%, or 40%, or 45%, 50%, 55%, 60%, 65% or above 65%.

In an embodiment, the exposure to erdafitinib is such that it providesfor an objective response rate, depending on the cancer type, of atleast 15%, or 20%, or 25%, or 30%, or 35%, or 40%, or 45%, 50%, 55%,60%, 65% or above 65%.

In an embodiment, the serum phosphate levels of the cancer patient is≥5.5 mg/dL, in particular ranging from and including 5.5 mg/dL to <7mg/dL or ranging from and including 5.5 mg/dL to ≤9 mg/dL, upon exposureto erdafitinib providing for an objective response rate, depending onthe cancer type, of at least 15%, or 20%, or 25%, or 30%, or 35%, or40%, or 45%, 50%, 55%, 60%, 65% or above 65%.

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein provide for an objective response rate of atleast 15%, or 20%, or 25%, or 30%, or 35%, or 40%, or 45%, 50%, 55%,60%, 65% or above 65%.

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein, wherein the cancer is urothelial cancer,metastatic or surgically unresectable urothelial cancer, in particularurothelial cancer, metastatic or surgically unresectable urothelialcancer with selected FGFR genetic alterations, provide for an objectiveresponse rate of at least 40%, in particular is about 40%, is about 41%,is about 42%, is about 43%, is about 44%, is about 45%, is about 46%, isabout 47%, is about 48%, is about 49%, is about 50%. In particular, theobjective response rate ranges from 40% to 50%, or ranges from 40% to45%, or ranges from 42% to 45%,

In an embodiment, for patients with urothelial cancer, metastatic orsurgically unresectable urothelial cancer, in particular urothelialcancer, metastatic or surgically unresectable urothelial cancer withselected FGFR genetic alterations, the objective response rate uponexposure to erdafitinib according to the dosing regimens as disclosedherein, is at least 40%, in particular is about 40%, is about 41%, isabout 42%, is about 43%, is about 44%, is about 45%, is about 46%, isabout 47%, is about 48%, is about 49%, is about 50%. In particular, theobjective response rate ranges from 40% to 50%, or ranges from 40% to45%, or ranges from 42% to 45%,

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein provide for a median duration of response ofat least 4 months, or at least 5 months, or at least 6 months, or atleast 7 months.

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein, wherein the cancer is urothelial cancer,metastatic or surgically unresectable urothelial cancer, in particularurothelial cancer, metastatic or surgically unresectable urothelialcancer with selected FGFR genetic alterations, provide for a medianduration of response of at least 4 months, or at least 5 months, or atleast 6 months, or at least 7 months, or is about 4 months, or about 5months or about 6 months or about 7 months. In particular, the medianduration of response ranges between 4 months and 7 months.

In an embodiment, for patients with urothelial cancer, metastatic orsurgically unresectable urothelial cancer, in particular urothelialcancer, metastatic or surgically unresectable urothelial cancer withselected FGFR genetic alterations, the median duration of response uponexposure to erdafitinib according to the dosing regimens as disclosedherein, is at least 4 months, or at least 5 months, or at least 6months, or at least 7 months, or is about 4 months, or about 5 months orabout 6 months or about 7 months. In particular, the median duration ofresponse ranges between 4 months and 7 months.

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein provide for a median progression freesurvival of at least 4 months, or at least 5 months, or at least 6months, or at least 7 months.

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein, wherein the cancer is urothelial cancer,metastatic or surgically unresectable urothelial cancer, in particularurothelial cancer, metastatic or surgically unresectable urothelialcancer with selected FGFR genetic alterations, provide for a medianprogression free survival of at least 4 months, or at least 5 months, orat least 6 months, or at least 7 months, or is about 4 months, or about5 months or about 6 months or about 7 months. In particular, the medianprogression free survival ranges between 4 months and 7 months.

In an embodiment, for patients with urothelial cancer, metastatic orsurgically unresectable urothelial cancer, in particular urothelialcancer, metastatic or surgically unresectable urothelial cancer withselected FGFR genetic alterations, the median progression free survivalupon exposure to erdafitinib according to the dosing regimens asdisclosed herein, is at least 4 months, or at least 5 months, or atleast 6 months, or at least 7 months, or is about 4 months, or about 5months or about 6 months or about 7 months. In particular, the medianprogression free survival ranges between 4 months and 7 months.

The median time to response to the methods of treatment of cancer asdescribed herein or the uses for the manufacture of a medicament for thetreatment of cancer as described herein or erdafitinib for use in thetreatment of cancer as described herein is very short. In an embodiment,the median time to response is less than 2 months, in particular lessthan 1.5 months, in particular is around 1.4 months.

In an embodiment, the methods of treatment of cancer as described hereinor the uses for the manufacture of a medicament for the treatment ofcancer as described herein or erdafitinib for use in the treatment ofcancer as described herein, wherein the cancer is urothelial cancer,metastatic or surgically unresectable urothelial cancer, in particularurothelial cancer, metastatic or surgically unresectable urothelialcancer with selected FGFR genetic alterations, provide for a median timeto response of less than 2 months, in particular less than 1.5 months,in particular is around 1.4 months.

In an embodiment, for patients with urothelial cancer, metastatic orsurgically unresectable urothelial cancer, in particular urothelialcancer, metastatic or surgically unresectable urothelial cancer withselected FGFR genetic alterations, the median time to response uponexposure to erdafitinib according to the dosing regimens as disclosedherein, is less than 2 months, in particular less than 1.5 months, inparticular is around 1.4 months.

Unexpectedly, it was found that the response to the treatments of canceras described herein, in particular the treatment of urothelial cancer,metastatic or surgically unresectable urothelial cancer, in particularurothelial cancer, metastatic or surgically unresectable urothelialcancer with selected FGFR genetic alterations, is independent of thenumber of prior lines treatment received by the patient, e.g. achemo-naïve patient, in particular a chemo-naïve patient ineligible forcisplatin, a patient who had disease progression after one prior line ofchemotherapy or a patient who had disease progression after two or moreprior lines of chemotherapy. In an embodiment, the response to thetreatment is similar for patients with different numbers of prior linesof treatment received, e.g. a chemo-naïve patient, in particular achemo-naïve patient ineligible for cisplatin, a patient who had diseaseprogression after one prior line of chemotherapy or a patient who haddisease progression after two or more prior lines of chemotherapy. In anembodiment, the response to the treatments of cancer by patients withprior line chemotherapy, e.g. a patient who had disease progressionafter one prior line of chemotherapy or a patient who had diseaseprogression after two or more prior lines of chemotherapy, is not worsethan for chemo-naïve patients.

It has been found that serum phosphate levels of ≥7 mg/dL, inparticular >9 mg/dL, may warrant temporary erdafitinib treatmentinterruption or erdafitinib dose adjustment (dose decrease).

In an embodiment temporary erdafitinib interruption representsinterruption of erdafitinib administration until serum phosphate levelsare again <5.5 mg/dL.

In an embodiment temporary erdafitinib interruption representsinterruption of erdafitinib administration until serum phosphate levelsare again <7 mg/dL.

It has been found that an efficacious and safe treatment witherdafitinib is administering erdafitinib in a therapeutically effectivedose such that the serum phosphate levels range from and including 5.5mg/dL to <7 mg/dL or range from and including 5.5 mg/dL to ≤9 mg/dL.

Serum phosphate levels can be measured with commercially available kitssuch as for example ab65622 Phosphate Assay Kit (Colorimetric) (Abcam).

It has been found that with a dose of 8 mg of erdafitinib daily,preferably once daily, on a continuous basis (every day, no treatmentinterruption, no intermittent administration unless the contextsindicates differently) the potential for the subject in need oferdafitinib administration, in particular the cancer patient, to reachor cross the 5.5 mg/dL serum phosphate levels increases, whileminimizing the need for treatment interruption or dose reduction forpotential drug related adverse events.

It has been found that with a dose of 8 mg of erdafitinib daily,preferably once daily, on a continuous basis the 5.5 mg/dL serumphosphate levels may be reached in the first cycle (set at, for example,the first 28 days or the first 21 days) of erdafitinib treatment. It hasbeen found that with a dose of 8 mg of erdafitinib daily, preferablyonce daily, on a continuous basis the potential for the subject in needof erdafitinib administration, in particular the cancer patient, toreach or cross the 5.5 mg/dL serum phosphate levels early enough duringthe first cycle (e.g. at day 14±2 days of the treatment) of erdafitinibtreatment increases to maximize efficacious treatment while minimizingthe need for treatment interruption or dose reduction for potential drugrelated adverse events.

In an embodiment the serum phosphate levels of the subject in need oferdafitinib treatment, in particular the cancer patient, are monitored.

In an embodiment the serum phosphate levels of the subject in need oferdafitinib treatment, in particular the cancer patient, are monitoredand early onset toxicity linked to FGFR inhibitors in general or toerdafitinib specifically shown by the subject, in need of erdafitinibtreatment, in particular the cancer patient, are monitored.

In an embodiment early onset toxicity linked to FGFR inhibitors ingeneral or to erdafitinib specifically comprise grade 3 or higherxerostomia or stomatitis/mucositis, dry skin, dry eye, nail toxicity (orgrade 2 if lasting more than 1 week) or grade 2 or higher eye toxicity(keratitis, central serious retinopathy/retinal pigment epithelialdetachments). Early onset toxicity may warrant treatment interruption ordose reduction. It is up to the discretion of the physician and it maydepend on the disease state of the patient.

In an embodiment early onset toxicity or early onset toxicity linked toFGFR inhibitors in general or to erdafitinib specifically as describedherein means clinically significant toxicity considered related to FGFRinhibitors in general or to erdafitinib specifically, usually consideredto be grade 3 or higher, consisting of one or more of the following:stomatitis/mucositis, dry skin, dry eye, nail toxicity or specific eyetoxicity (keratitis, or retinopathy also described as central serousretinopathy, retinal detachment, retinal edema, retinal pigmentepithelial detachment, chorioretinopathy) or pertaining to othersignificant toxicity considered related to FGFR inhibitors in general orto erdafitinib specifically. Early onset toxicity may warrant treatmentinterruption or dose reduction. It is up to the discretion of thephysician and it may depend on the disease state of the patient.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, an amount of erdafitinib so that the levelsof serum phosphate range from and including 5.5 mg/dL to <7 mg/dL. In anembodiment, the amount of erdafitinib is 8 mg, in particular 8 mg dailyadministered on a continuous basis. The present invention concerns amethod for the treatment of cancer, which method comprises administeringto a subject in need thereof, in particular a cancer patient, an amountof erdafitinib so that the levels of serum phosphate attain, within thefirst cycle of erdafitinib administration (a treatment cycle durationset at, for example, the first 28 days of administration or the first 21days of administration and the serum phosphate level assessed at oraround the 28^(th) day, or at or around the 21^(st) day or at or aroundthe 14^(th) day of administration) the range from and including 5.5mg/dL to <7 mg/dL. In an embodiment, the amount of erdafitinib is 8 mg,in particular 8 mg daily administered on a continuous basis.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, an amount of erdafitinib so that the levelsof serum phosphate range from and including 5.5 mg/dL to ≤9 mg/dL. In anembodiment, the amount of erdafitinib is 8 mg, in particular 8 mg dailyadministered on a continuous basis. The present invention concerns amethod for the treatment of cancer, which method comprises administeringto a subject in need thereof, in particular a cancer patient, an amountof erdafitinib so that the levels of serum phosphate attain, within thefirst cycle of erdafitinib administration (a treatment cycle durationset at, for example, the first 28 days of administration or the first 21days of administration and the serum phosphate level assessed at oraround the 28^(th) day, or at or around the 21^(st) day or at or aroundthe 14^(th) day of administration) the range from and including 5.5mg/dL to ≤9 mg/dL. In an embodiment, the amount of erdafitinib is 8 mg,in particular 8 mg daily administered on a continuous basis.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer, in an amount sothat the levels of serum phosphate range from and including 5.5 mg/dL to<7 mg/dL. The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer, in an amount sothat the levels of serum phosphate attain, within the first cycle oferdafitinib administration (a treatment cycle duration set at, forexample, the first 28 days of administration or the first 21 days ofadministration and the serum phosphate level assessed at or around the28^(th) day, or at or around the 21^(st) day or at or around the 14^(th)day of administration) the range from and including 5.5 mg/dL to <7mg/dL. In an embodiment, the amount of erdafitinib is 8 mg, inparticular 8 mg daily administered on a continuous basis.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer, in an amount sothat the levels of serum phosphate range from and including 5.5 mg/dL to≤9 mg/dL. The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer, in an amount sothat the levels of serum phosphate attain, within the first cycle oferdafitinib administration (a treatment cycle duration set at, forexample, the first 28 days of administration or the first 21 days ofadministration and the serum phosphate level assessed at or around the28^(th) day, or at or around the 21^(st) day or at or around the 14^(th)day of administration) the range from and including 5.5 mg/dL to ≤9mg/dL. In an embodiment, the amount of erdafitinib is 8 mg, inparticular 8 mg daily administered on a continuous basis.

The present invention concerns erdafitinib for use in the treatment ofcancer, wherein erdafitinib is administered in an amount so that thelevels of serum phosphate range from and including 5.5 mg/dL to <7mg/dL. The present invention concerns erdafitinib for use in thetreatment of cancer, wherein erdafitinib is administered in an amount sothat the levels of serum phosphate attain, within the first cycle oferdafitinib administration (a treatment cycle duration set at, forexample, the first 28 days of administration or the first 21 days ofadministration and the serum phosphate level assessed at or around the28^(th) day, or at or around the 21^(st) day or at or around the 14^(th)day of administration) the range from and including 5.5 mg/dL to <7mg/dL. In an embodiment, the amount of erdafitinib is 8 mg, inparticular 8 mg daily administered on a continuous basis.

The present invention concerns erdafitinib for use in the treatment ofcancer, wherein erdafitinib is administered in an amount so that thelevels of serum phosphate range from and including 5.5 mg/dL to ≤9mg/dL. The present invention concerns erdafitinib for use in thetreatment of cancer, wherein erdafitinib is administered in an amount sothat the levels of serum phosphate attain, within the first cycle oferdafitinib administration (a treatment cycle duration set at, forexample, the first 28 days of administration or the first 21 days ofadministration and the serum phosphate level assessed at or around the28^(th) day, or at or around the 21^(st) day or at or around the 14^(th)day of administration) the range from and including 5.5 mg/dL to ≤9mg/dL. In an embodiment, the amount of erdafitinib is 8 mg, inparticular 8 mg daily administered on a continuous basis.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 8 mg of erdafitinib daily, in particularonce daily, on a continuous basis. Dose adjustment may be done based onserum phosphate level and observed or absence of toxicity.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer, wherein themedicament comprises erdafitinib in an amount of 8 mg and wherein themedicament is for daily, in particular once daily, administration on acontinuous basis. Dose adjustment may be done based on serum phosphatelevel and observed or absence of toxicity.

The present invention concerns erdafitinib for use in the treatment ofcancer, wherein erdafitinib is administered in an amount of 8 mg daily,in particular once daily, on a continuous basis. Dose adjustment may bedone based on serum phosphate level and observed or absence of toxicity.

During the treatment of erdafitinib at a dose of 8 mg daily, preferablyonce daily, on a continuous basis, serum phosphate levels can bemonitored. If the levels of serum phosphate are <5.5 mg/dL, then thedose of erdafitinib can be increased, can be up-titrated to 9 mg daily,preferably once daily, on a continuous basis. In an embodiment, thelevels of serum phosphate for determining whether or not to up-titrateare measured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration.

During the treatment of erdafitinib at a dose of 8 mg daily, preferablyonce daily, on a continuous basis, serum phosphate levels can bemonitored. If the levels of serum phosphate are <7 mg/dL or range fromand include 7 mg/dL to ≤9 mg/dL or are ≤9 mg/dL, then the dose oferdafitinib can be increased, can be up-titrated to 9 mg daily,preferably once daily, on a continuous basis. In an embodiment, thelevels of serum phosphate for determining whether or not to up-titrateare measured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 8 mg of erdafitinib daily, in particularonce daily, on a continuous basis which method comprises monitoring ofserum phosphate levels of the subject. In an embodiment, the levels ofserum phosphate for determining whether or not to up-titrate aremeasured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 8mg, wherein the medicament is for daily, in particular once daily,administration on a continuous basis and wherein serum phosphate levelsof the cancer patient are monitored. In an embodiment, the levels ofserum phosphate for determining whether or not to up-titrate aremeasured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 8 mg daily, in particular once daily, on a continuous basisand wherein the serum phosphate levels of the cancer patient aremonitored. In an embodiment, the levels of serum phosphate fordetermining whether or not to up-titrate are measured on a treatment dayduring the first cycle of erdafitinib treatment, in particular on day14±2 days, more in particular on day 14, of erdafitinib administration.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 8 mg of erdafitinib daily, in particularonce daily, on a continuous basis, which method comprises monitoring ofserum phosphate levels of the subject and when the serum phosphatelevels are <5.5 mg/dL, the daily amount, preferably the once dailyamount, of erdafitinib administered on a continuous basis, is increasedto 9 mg. When the serum phosphate levels range from and including 5.5mg/dL to <7 mg/dL, the subject remains on the 8 mg daily continuoustreatment. When the serum phosphate levels are ≥7 mg/dL, the treatmentis interrupted temporarily, in particular erdafitinib treatment isinterrupted until serum phosphate levels are again <7 mg/dL, or thedaily continuous dose is adjusted to <8 mg, in particular the treatmentis interrupted temporarily, in particular until serum phosphate levelsare <5.5 mg/dL. In an embodiment, the levels of serum phosphate aremeasured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration. In an embodiment, when the serumphosphate levels are ≥7 mg/dL, in particular range from and including 7mg/dL to ≤9 mg/dL, in particular on day 14±2 days, more in particular onday 14, the treatment is interrupted temporarily until serum phosphatelevels are <5.5 mg/dL and then erdafitinib treatment is re-started with8 mg daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 8 mg of erdafitinib daily, in particularonce daily, on a continuous basis, which method comprises monitoring ofserum phosphate levels of the subject and when the serum phosphatelevels are <7 mg/dL, the daily amount, preferably the once daily amount,of erdafitinib administered on a continuous basis, is increased to 9 mg.When the serum phosphate levels range from and including 7 mg/dL to ≤9mg/dL, the daily amount, preferably the once daily amount, oferdafitinib administered on a continuous basis, is increased to 9 mg,while concurrently treatment with a phosphate binder, such as forexample sevelamer, is optionally initiated. In an embodiment, concurrenttreatment with a phosphate binder, such as for example sevelamer, isinitiated. When the serum phosphate levels are elevated to >9 mg/dL, thetreatment is interrupted temporarily, in particular erdafitinibtreatment is interrupted until serum phosphate levels are again <7mg/dL, and, upon serum phosphate being below 7 mg/dL, the dailycontinuous dose is adjusted to the same or a lower daily dose. In caseof persistent serum phosphate levels ≥10 mg/dL for >2 weeks, thetreatment is interrupted permanently, in particular erdafitinibtreatment is interrupted permanently. In an embodiment, the levels ofserum phosphate are measured on a treatment day during the first cycleof erdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration. In an embodiment,when the serum phosphate levels are >9 mg/dL, the treatment isinterrupted temporarily until serum phosphate levels are <7 mg/dL andthen erdafitinib treatment is re-started with 8 mg daily, in particularonce daily, on a continuous basis. In an embodiment, serum phosphatelevels during further erdafitinib administration may be managedaccording to Table 4.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 8 mg of erdafitinib daily, in particularonce daily, on a continuous basis, which method comprises monitoring ofserum phosphate levels of the subject and monitoring of early onsettoxicity linked to FGFR inhibitors in general or to erdafitinibspecifically shown by the subject, and when the serum phosphate levelsare <5.5 mg/dL and no early onset toxicity is shown, the daily amount,preferably the once daily amount, of erdafitinib administered on acontinuous basis, is increased to 9 mg. When the serum phosphate levelsrange from and including 5.5 mg/dL to <7 mg/dL and no early onsettoxicity is shown, the subject remains on the 8 mg daily continuoustreatment. When the serum phosphate levels are ≥7 mg/dL, the treatmentis interrupted temporarily, in particular erdafitinib treatment isinterrupted until serum phosphate levels are again <7 mg/dL, or thedaily continuous dose is adjusted to <8 mg, in particular the treatmentis interrupted temporarily, in particular until serum phosphate levelsare <5.5 mg/dL. In an embodiment, the levels of serum phosphate aremeasured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration. In an embodiment, when the serumphosphate levels are ≥7 mg/dL, the treatment is interrupted temporarilyuntil serum phosphate levels are <5.5 mg/dL and then erdafitinibtreatment is re-started with 8 mg daily, in particular once daily, on acontinuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 8 mg of erdafitinib daily, in particularonce daily, on a continuous basis, which method comprises monitoring ofserum phosphate levels of the subject and monitoring of early onsettoxicity linked to FGFR inhibitors in general or to erdafitinibspecifically shown by the subject, and when the serum phosphate levelsare <7 mg/dL and no early onset toxicity is shown, the daily amount,preferably the once daily amount, of erdafitinib administered on acontinuous basis, is increased to 9 mg. When the serum phosphate levelsrange from and including 7 mg/dL to ≤9 mg/dL and no early onset toxicityis shown, the daily amount, preferably the once daily amount, oferdafitinib administered on a continuous basis, is increased to 9 mg,while concurrently treatment with a phosphate binder, such as forexample sevelamer, is optionally initiated. In an embodiment, concurrenttreatment with a phosphate binder, such as for example sevelamer, isinitiated. When the serum phosphate levels are elevated >9 mg/dL, thetreatment is interrupted temporarily, in particular erdafitinibtreatment is interrupted until serum phosphate levels are again <7mg/dL, and, upon serum phosphate being below 7 mg/dL, the dailycontinuous dose is adjusted to the same or a lower daily dose. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration. In an embodiment, when the serum phosphate levels are >9mg/dL, the treatment is interrupted temporarily until serum phosphatelevels are <7 mg/dL and then erdafitinib treatment is re-started with 8mg daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 9 mg of erdafitinib daily, in particularonce daily, on a continuous basis, which method comprises monitoring ofserum phosphate levels of the subject and wherein the 9 mg isadministered to the subject when the serum phosphate levels of saidsubject are <5.5 mg/dL while being on a treatment with erdafitinib 8 mgdaily, in particular once daily, on a continuous basis. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 9 mg of erdafitinib daily, in particularonce daily, on a continuous basis, wherein the 9 mg is administered tothe subject when the serum phosphate levels of said subject are <7 mg/dLor when the serum phosphate levels range from and including 7 mg/dL to≤9 mg/dL, while being on a treatment with erdafitinib 8 mg daily, inparticular once daily, on a continuous basis. When the serum phosphatelevels range from and including 7 mg/dL to ≤9 mg/dL, concurrenttreatment with a phosphate binder, such as for example sevelamer, may beinitiated. In an embodiment, concurrent treatment with a phosphatebinder, such as for example sevelamer, is initiated. In an embodiment,the levels of serum phosphate are measured on day 14±2 days, inparticular on day 14, of erdafitinib administration. In an embodiment,serum phosphate levels during further erdafitinib administration may bemanaged according to Table 4.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 9 mg of erdafitinib daily, in particularonce daily, on a continuous basis, wherein the 9 mg is administered tothe subject when the serum phosphate levels of said subject are <5.5mg/dL and no early onset toxicity is shown while being on a treatmentwith erdafitinib 8 mg daily, in particular once daily, on a continuousbasis. In an embodiment, the levels of serum phosphate are measured on atreatment day during the first cycle of erdafitinib treatment, inparticular on day 14±2 days, more in particular on day 14, oferdafitinib administration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns a method for the treatment of cancer,which method comprises administering to a subject in need thereof, inparticular a cancer patient, 9 mg of erdafitinib daily, in particularonce daily, on a continuous basis, wherein the 9 mg is administered tothe cancer patient when the serum phosphate levels of said patient are<7 mg/dL or when the serum phosphate levels range from and including 7mg/dL to ≤9 mg/dL, and no early onset toxicity is shown while being on atreatment with erdafitinib 8 mg daily, in particular once daily, on acontinuous basis. When the serum phosphate levels range from andincluding 7 mg/dL to ≤9 mg/dL and no early onset toxicity is shown,concurrent treatment with a phosphate binder, such as for examplesevelamer, may be initiated. In an embodiment, concurrent treatment witha phosphate binder, such as for example sevelamer, is initiated. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 8mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein serum phosphate levels ofthe cancer patient are monitored and when the serum phosphate levels are<5.5 mg/dL, the amount of erdafitinib in the medicament for daily, inparticular once daily, administration on a continuous basis is increasedto 9 mg. When the serum phosphate levels range from and including 5.5mg/dL to <7 mg/dL, the patient remains on the 8 mg daily continuoustreatment. When the serum phosphate levels are ≥7 mg/dL, the treatmentis interrupted temporarily, in particular erdafitinib treatment isinterrupted until serum phosphate levels are again <7 mg/dL, or thedaily continuous dose is adjusted to <8 mg, in particular the treatmentis interrupted temporarily, in particular until serum phosphate levelsare <5.5 mg/dL. In an embodiment, the levels of serum phosphate aremeasured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration. In an embodiment, when the serumphosphate levels are ≥7 mg/dL, the treatment is interrupted temporarilyuntil serum phosphate levels are <5.5 mg/dL and then erdafitinibtreatment is re-started with 8 mg daily, in particular once daily, on acontinuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 8mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein serum phosphate levels ofthe cancer patient are monitored and when the serum phosphate levels are<7 mg/dL, the amount of erdafitinib in the medicament for daily, inparticular once daily, administration on a continuous basis, isincreased to 9 mg. When the serum phosphate levels range from andincluding 7 mg/dL to ≤9 mg/dL, the amount of erdafitinib for daily, inparticular once daily, administration on a continuous basis, isincreased to 9 mg, while concurrently treatment with a phosphate binder,such as for example sevelamer, is optionally initiated.

In an embodiment, concurrent treatment with a phosphate binder, such asfor example sevelamer, is initiated. When the serum phosphate levels areelevated >9 mg/dL, the treatment is interrupted temporarily, inparticular erdafitinib treatment is interrupted until serum phosphatelevels are again <7 mg/dL, and, upon serum phosphate being below 7mg/dL, the daily continuous dose is adjusted to the same or a lowerdaily dose. In an embodiment, the levels of serum phosphate are measuredon a treatment day during the first cycle of erdafitinib treatment, inparticular on day 14±2 days, more in particular on day 14, oferdafitinib administration. In an embodiment, when the serum phosphatelevels are >9 mg/dL, the treatment is interrupted temporarily untilserum phosphate levels are <7 mg/dL and then erdafitinib treatment isre-started with 8 mg daily, in particular once daily, on a continuousbasis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 8mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein serum phosphate levels ofthe cancer patient are monitored and early onset toxicity linked to FGFRinhibitors in general or to erdafitinib specifically shown by the cancerpatient is monitored, and when the serum phosphate levels are <5.5 mg/dLand no early onset toxicity is shown, the amount of erdafitinib in themedicament for daily, in particular once daily, administration on acontinuous basis is increased to 9 mg. When the serum phosphate levelsrange from and including 5.5 mg/dL to <7 mg/dL and no early onsettoxicity is shown, the patient remains on the 8 mg daily continuoustreatment. When the serum phosphate levels are ≥7 mg/dL, the treatmentis interrupted temporarily, in particular erdafitinib treatment isinterrupted until serum phosphate levels are again <7 mg/dL, or thedaily continuous dose is adjusted to <8 mg, in particular the treatmentis interrupted temporarily, in particular until serum phosphate levelsare <5.5 mg/dL. In an embodiment, the levels of serum phosphate aremeasured on a treatment day during the first cycle of erdafitinibtreatment, in particular on day 14±2 days, more in particular on day 14,of erdafitinib administration. In an embodiment, when the serumphosphate levels are ≥7 mg/dL, the treatment is interrupted temporarilyuntil serum phosphate levels are <5.5 mg/dL and then erdafitinibtreatment is re-started with 8 mg daily, in particular once daily, on acontinuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 8mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein serum phosphate levels ofthe cancer patient are monitored and early onset toxicity linked to FGFRinhibitors in general or to erdafitinib specifically shown by the cancerpatient is monitored, and when the serum phosphate levels are <7 mg/dLand no early onset toxicity is shown, the amount of erdafitinib in themedicament for daily, in particular once daily, administration on acontinuous basis, is increased to 9 mg. When the serum phosphate levelsrange from and including 7 mg/dL to ≤9 mg/dL and no early onset toxicityis shown, the amount of erdafitinib for daily, in particular once daily,administration on a continuous basis, is increased to 9 mg, whileconcurrently treatment with a phosphate binder, such as for examplesevelamer, is optionally initiated. In an embodiment, concurrenttreatment with a phosphate binder, such as for example sevelamer, isinitiated. When the serum phosphate levels are elevated >9 mg/dL, thetreatment is interrupted temporarily, in particular erdafitinibtreatment is interrupted until serum phosphate levels are again <7mg/dL, and, upon serum phosphate being below 7 mg/dL, the dailycontinuous dose is adjusted to the same or a lower daily dose. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration. In an embodiment, when the serum phosphate levels are >9mg/dL, the treatment is interrupted temporarily until serum phosphatelevels are <7 mg/dL and then erdafitinib treatment is re-started with 8mg daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 9mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein the medicament isadministered to the cancer patient when the serum phosphate levels ofsaid patient are <5.5 mg/dL while being on a treatment with erdafitinib8 mg daily, in particular once daily, on a continuous basis. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 9mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein the medicament isadministered to the cancer patient when the serum phosphate levels ofsaid patient are <7 mg/dL or when the serum phosphate levels range fromand including 7 mg/dL to ≤9 mg/dL, while being on a treatment witherdafitinib 8 mg daily, in particular once daily, on a continuous basis.When the serum phosphate levels range from and including 7 mg/dL to ≤9mg/dL, concurrent treatment with a phosphate binder, such as for examplesevelamer, may be initiated. In an embodiment, concurrent treatment witha phosphate binder, such as for example sevelamer, is initiated. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 9mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein the medicament isadministered to the cancer patient when the serum phosphate levels ofsaid patient are <5.5 mg/dL and no early onset toxicity is shown whilebeing on a treatment with erdafitinib 8 mg daily, in particular oncedaily, on a continuous basis. In an embodiment, the levels of serumphosphate are measured on a treatment day during the first cycle oferdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration. In an embodiment,serum phosphate levels during further erdafitinib administration may bemanaged according to Table 3.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein the medicament comprises erdafitinib in an amount of 9mg and wherein the medicament is for daily, in particular once daily,administration on a continuous basis, wherein the medicament isadministered to the cancer patient when the serum phosphate levels ofsaid patient are <7 mg/dL or when the serum phosphate levels range fromand including 7 mg/dL to ≤9 mg/dL, and no early onset toxicity is shownwhile being on a treatment with erdafitinib 8 mg daily, in particularonce daily, on a continuous basis. When the serum phosphate levels rangefrom and including 7 mg/dL to ≤9 mg/dL and no early onset toxicity isshown, concurrent treatment with a phosphate binder, such as for examplesevelamer, may be initiated. In an embodiment, concurrent treatment witha phosphate binder, such as for example sevelamer, is initiated. In anembodiment, the levels of serum phosphate are measured on a treatmentday during the first cycle of erdafitinib treatment, in particular onday 14±2 days, more in particular on day 14, of erdafitinibadministration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 8 mg daily, in particular once daily, on a continuous basis,wherein the serum phosphate levels in the cancer patient are monitoredand when the serum phosphate levels are <5.5 mg/dL, the amount oferdafitinib administered daily, preferably once daily, on a continuousbasis, is increased to 9 mg. When the serum phosphate levels range fromand including 5.5 mg/dL to <7 mg/dL, the patient remains on the 8 mgdaily continuous treatment. When the serum phosphate levels are ≥7mg/dL, the treatment is interrupted temporarily, in particularerdafitinib treatment is interrupted until serum phosphate levels areagain <7 mg/dL, or the daily continuous dose is adjusted to <8 mg, inparticular the treatment is interrupted temporarily, in particular untilserum phosphate levels are <5.5 mg/dL. In an embodiment, the levels ofserum phosphate are measured on a treatment day during the first cycleof erdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration. In an embodiment,when the serum phosphate levels are ≥7 mg/dL, the treatment isinterrupted temporarily until serum phosphate levels are <5.5 mg/dL andthen erdafitinib treatment is re-started with 8 mg daily, in particularonce daily, on a continuous basis. In an embodiment, serum phosphatelevels during further erdafitinib administration may be managedaccording to Table 3.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 8 mg daily, in particular once daily, on a continuous basis,wherein the serum phosphate levels in the cancer patient are monitoredand when the serum phosphate levels are <7 mg/dL or when the serumphosphate levels range from and including 7 mg/dL to ≤9 mg/dL, theamount of erdafitinib administered daily, preferably once daily, on acontinuous basis, is increased to 9 mg. When the serum phosphate levelsrange from and including 7 mg/dL to ≤9 mg/dL, concurrent treatment witha phosphate binder, such as for example sevelamer, may be initiated. Inan embodiment, concurrent treatment with a phosphate binder, such as forexample sevelamer, is initiated. When the serum phosphate levels areelevated >9 mg/dL, the treatment is interrupted temporarily, inparticular erdafitinib treatment is interrupted until serum phosphatelevels are again <7 mg/dL, and, upon serum phosphate being below 7mg/dL, the daily continuous dose is adjusted to the same or a lowerdaily dose. In an embodiment, the levels of serum phosphate are measuredon a treatment day during the first cycle of erdafitinib treatment, inparticular on day 14±2 days, more in particular on day 14, oferdafitinib administration. In an embodiment, when the serum phosphatelevels are >9 mg/dL, the treatment is interrupted temporarily untilserum phosphate levels are <7 mg/dL and then erdafitinib treatment isre-started with 8 mg daily, in particular once daily, on a continuousbasis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 8 mg daily, in particular once daily, on a continuous basis,wherein the serum phosphate levels in the cancer patient are monitoredand early onset toxicity linked to FGFR inhibitors in general or toerdafitinib specifically shown by the cancer patient is monitored, andwhen the serum phosphate levels are <5.5 mg/dL and no early onsettoxicity is shown, the amount of erdafitinib administered daily,preferably once daily, on a continuous basis, is increased to 9 mg. Whenthe serum phosphate levels range from and including 5.5 mg/dL to <7mg/dL and no early onset toxicity is shown, the patient remains on the 8mg daily continuous treatment. When the serum phosphate levels are ≥7mg/dL, the treatment is interrupted temporarily, in particularerdafitinib treatment is interrupted until serum phosphate levels areagain <7 mg/dL, or the daily continuous dose is adjusted to <8 mg, inparticular the treatment is interrupted temporarily, in particular untilserum phosphate levels are <5.5 mg/dL. In an embodiment, the levels ofserum phosphate are measured on a treatment day during the first cycleof erdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration. In an embodiment,when the serum phosphate levels are ≥7 mg/dL, the treatment isinterrupted temporarily until serum phosphate levels are <5.5 mg/dL andthen erdafitinib treatment is re-started with 8 mg daily, in particularonce daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 8 mg daily, in particular once daily, on a continuous basis,wherein the serum phosphate levels in the cancer patient are monitoredand early onset toxicity linked to FGFR inhibitors in general or toerdafitinib specifically shown by the cancer patient is monitored, andwhen the serum phosphate levels are <7 mg/dL or when the serum phosphatelevels range from and including 7 mg/dL to ≤9 mg/dL, the amount oferdafitinib administered daily, preferably once daily, on a continuousbasis, is increased to 9 mg. When the serum phosphate levels range fromand including 7 mg/dL to ≤9 mg/dL, concurrent treatment with a phosphatebinder, such as for example sevelamer, may be initiated. In anembodiment, concurrent treatment with a phosphate binder, such as forexample sevelamer, is initiated. When the serum phosphate levels areelevated >9 mg/dL, the treatment is interrupted temporarily, inparticular erdafitinib treatment is interrupted until serum phosphatelevels are again <7 mg/dL, and, upon serum phosphate being below 7mg/dL, the daily continuous dose is adjusted to the same or a lowerdaily dose. In an embodiment, the levels of serum phosphate are measuredon a treatment day during the first cycle of erdafitinib treatment, inparticular on day 14±2 days, more in particular on day 14, oferdafitinib administration. In an embodiment, when the serum phosphatelevels are >9 mg/dL, the treatment is interrupted temporarily untilserum phosphate levels are <7 mg/dL and then erdafitinib treatment isre-started with 8 mg daily, in particular once daily, on a continuousbasis. In an embodiment, serum phosphate levels during furthererdafitinib administration may be managed according to Table 4.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 9 mg daily, in particular once daily, on a continuous basis,when the serum phosphate levels of said patient are <5.5 mg/dL whilebeing on a treatment with erdafitinib 8 mg daily, in particular oncedaily, on a continuous basis. In an embodiment, the levels of serumphosphate are measured on a treatment day during the first cycle oferdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 9 mg daily, in particular once daily, on a continuous basis,when the serum phosphate levels of said patient are <7 mg/dL or when theserum phosphate levels range from and including 7 mg/dL to ≤9 mg/dL,while being on a treatment with erdafitinib 8 mg daily, in particularonce daily, on a continuous basis. When the serum phosphate levels rangefrom and including 7 mg/dL to ≤9 mg/dL, concurrent treatment with aphosphate binder, such as for example sevelamer, may be initiated. In anembodiment, concurrent treatment with a phosphate binder, such as forexample sevelamer, is initiated. In an embodiment, the levels of serumphosphate are measured on a treatment day during the first cycle oferdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration. In an embodiment,serum phosphate levels during further erdafitinib administration may bemanaged according to Table 4.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 9 mg daily, in particular once daily, on a continuous basis,when the serum phosphate levels of said patient are <5.5 mg/dL and noearly onset toxicity is shown while being on a treatment witherdafitinib 8 mg daily, in particular once daily, on a continuous basis.In an embodiment, the levels of serum phosphate are measured on atreatment day during the first cycle of erdafitinib treatment, inparticular on day 14±2 days, more in particular on day 14, oferdafitinib administration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein erdafitinib is administered in anamount of 9 mg daily, in particular once daily, on a continuous basis,when the serum phosphate levels of said patient are <7 mg/dL or when theserum phosphate levels range from and including 7 mg/dL to ≤9 mg/dL, andno early onset toxicity is shown while being on a treatment witherdafitinib 8 mg daily, in particular once daily, on a continuous basis.When the serum phosphate levels range from and including 7 mg/dL to ≤9mg/dL and no early onset toxicity is shown, concurrent treatment with aphosphate binder, such as for example sevelamer, may be initiated. In anembodiment, concurrent treatment with a phosphate binder, such as forexample sevelamer, is initiated. In an embodiment, the levels of serumphosphate are measured on a treatment day during the first cycle oferdafitinib treatment, in particular on day 14±2 days, more inparticular on day 14, of erdafitinib administration.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

In an embodiment of the invention, the serum phosphate levels (todetermine whether the amount of erdafitinib can be increased from 8 mgdaily to 9 mg daily) are assessed when steady state levels oferdafitinib plasma concentration and serum phosphate are reached.

In an embodiment of the invention, the serum phosphate levels todetermine whether the amount of erdafitinib can be increased from 8 mgdaily to 9 mg daily are assessed at a treatment day during the firstcycle of erdafitinib treatment, in particular at approximately day 14±2days of erdafitinib treatment, in particular at day 14 of erdafitinibtreatment (day 14 of cycle 1 of erdafitinib treatment). In an embodimenta cycle is 21 days. In an embodiment a cycle is 28 days.

The daily amount of erdafitinib as mentioned herein can be administeredvia one pharmaceutical composition or via more than one pharmaceuticalcomposition. The medicament as mentioned herein can comprise onepharmaceutical composition or more than one pharmaceutical composition.In an embodiment, the 8 mg dose of erdafitinib can be administered as 2formulations, in particular 2 tablets, each comprising 4 mg oferdafitinib. In an embodiment, the 9 mg dose of erdafitinib can beadministered as 3 formulations, in particular 3 tablets, each comprising3 mg of erdafitinib.

The present invention concerns a method for the treatment of cancer,which method comprises

-   -   a) administering to a subject in need thereof, in particular a        cancer patient, 8 mg of erdafitinib daily, in particular once        daily, on a continuous basis;    -   b) measuring the serum phosphate levels of the subject on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <5.5 mg/dL, erdafitinib        is administered in an amount of 9 mg daily, in particular once        daily, on a continuous basis;    -   c-2) when the serum phosphate levels range from and including        5.5 mg/dL to <7 mg/dL, erdafitinib is further administered in an        amount of 8 mg daily, in particular once daily, on a continuous        basis;    -   c-3) when the serum phosphate levels are ≥7 mg/dL, the        erdafitinib treatment is interrupted temporarily until serum        phosphate levels are <5.5 mg/dL and then erdafitinib treatment        is re-started with 8 mg daily, in particular once daily, on a        continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns a method for the treatment of cancer,which method comprises

-   -   a) administering to a subject in need thereof, in particular a        cancer patient, 8 mg of erdafitinib daily, in particular once        daily, on a continuous basis;    -   b) measuring the serum phosphate levels of the subject on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <7 mg/dL or when the        serum phosphate levels range from and including 7 mg/dL to ≤9        mg/dL, erdafitinib is administered in an amount of 9 mg daily,        in particular once daily, on a continuous basis; and when the        serum phosphate levels range from and including 7 mg/dL to ≤9        mg/dL, concurrent treatment with a phosphate binder, such as for        example sevelamer, is optionally initiated;    -   c-2) when the serum phosphate levels are >9 mg/dL, the        erdafitinib treatment is interrupted temporarily until serum        phosphate levels are <7 mg/dL and then erdafitinib treatment is        re-started with 8 mg daily, in particular once daily, on a        continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns a method for the treatment of cancer,which method comprises

-   -   a) administering to a subject in need thereof, in particular a        cancer patient, 8 mg of erdafitinib daily, in particular once        daily, on a continuous basis;    -   b) measuring the serum phosphate levels of the subject on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <5.5 mg/dL and no early        onset toxicity is shown, erdafitinib is administered in an        amount of 9 mg daily, in particular once daily, on a continuous        basis;    -   c-2) when the serum phosphate levels range from and including        5.5 mg/dL to <7 mg/dL and no early onset toxicity is shown,        erdafitinib is further administered in an amount of 8 mg daily,        in particular once daily, on a continuous basis;    -   c-3) when the serum phosphate levels are ≥7 mg/dL and no early        onset toxicity is shown, the erdafitinib treatment is        interrupted temporarily until serum phosphate levels are <5.5        mg/dL and then erdafitinib treatment is re-started with 8 mg        daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns a method for the treatment of cancer,which method comprises

-   -   a) administering to a subject in need thereof, in particular a        cancer patient, 8 mg of erdafitinib daily, in particular once        daily, on a continuous basis;    -   b) measuring the serum phosphate levels of the subject on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <7 mg/dL and no early        onset toxicity is shown or when the serum phosphate levels range        from and including 7 mg/dL to ≤9 mg/dL and no early onset        toxicity is shown, erdafitinib is administered in an amount of 9        mg daily, in particular once daily, on a continuous basis; and        when the serum phosphate levels range from and including 7 mg/dL        to ≤9 mg/dL, concurrent treatment with a phosphate binder, such        as for example sevelamer, is optionally initiated;    -   c-2) when the serum phosphate levels are >9 mg/dL and no early        onset toxicity is shown, the erdafitinib treatment is        interrupted temporarily until serum phosphate levels are <7        mg/dL and then erdafitinib treatment is re-started with 8 mg        daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein

-   -   a) the medicament comprises erdafitinib in an amount of 8 mg and        wherein the medicament is for daily, in particular once daily,        administration on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <5.5 mg/dL, the amount        of erdafitinib in the medicament for daily, in particular once        daily, administration on a continuous basis is increased to 9        mg;    -   c-2) when the serum phosphate levels range from and including        5.5 mg/dL to <7 mg/dL, the patient remains on the 8 mg daily, in        particular once daily, continuous treatment;    -   c-3) when the serum phosphate levels are ≥7 mg/dL, the        erdafitinib treatment is interrupted temporarily until serum        phosphate levels are <5.5 mg/dL and then erdafitinib treatment        is re-started with 8 mg daily, in particular once daily, on a        continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein

-   -   a) the medicament comprises erdafitinib in an amount of 8 mg and        wherein the medicament is for daily, in particular once daily,        administration on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <7 mg/dL or when the        serum phosphate levels range from and including 7 mg/dL to ≤9        mg/dL, the amount of erdafitinib in the medicament for daily, in        particular once daily, administration on a continuous basis is        increased to 9 mg; and when the serum phosphate levels range        from and including 7 mg/dL to ≤9 mg/dL, concurrent treatment        with a phosphate binder, such as for example sevelamer, is        optionally initiated;    -   c-2) when the serum phosphate levels are >9 mg/dL, the        erdafitinib treatment is interrupted temporarily until serum        phosphate levels are <7 mg/dL and then erdafitinib treatment is        re-started with 8 mg daily, in particular once daily, on a        continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein

-   -   a) the medicament comprises erdafitinib in an amount of 8 mg and        wherein the medicament is for daily, in particular once daily,        administration on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <5.5 mg/dL and no early        onset toxicity is shown, the amount of erdafitinib in the        medicament for daily, in particular once daily, administration        on a continuous basis is increased to 9 mg;    -   c-2) when the serum phosphate levels range from and including        5.5 mg/dL to <7 mg/dL and no early onset toxicity is shown, the        patient remains on the 8 mg daily, in particular once daily,        continuous treatment;    -   c-3) when the serum phosphate levels are ≥7 mg/dL and no early        onset toxicity is shown, the erdafitinib treatment is        interrupted temporarily until serum phosphate levels are <5.5        mg/dL and then erdafitinib treatment is re-started with 8 mg        daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns the use of erdafitinib for themanufacture of a medicament for the treatment of cancer in a cancerpatient, wherein

-   -   a) the medicament comprises erdafitinib in an amount of 8 mg and        wherein the medicament is for daily, in particular once daily,        administration on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <7 mg/dL and no early        onset toxicity is shown or when the serum phosphate levels range        from and including 7 mg/dL to ≤9 mg/dL and no early onset        toxicity is shown, the amount of erdafitinib in the medicament        for daily, in particular once daily, administration on a        continuous basis is increased to 9 mg; and when the serum        phosphate levels range from and including 7 mg/dL to ≤9 mg/dL,        concurrent treatment with a phosphate binder, such as for        example sevelamer, is optionally initiated;    -   c-2) when the serum phosphate levels are >9 mg/dL and no early        onset toxicity is shown, the erdafitinib treatment is        interrupted temporarily until serum phosphate levels are <7        mg/dL and then erdafitinib treatment is re-started with 8 mg        daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein

-   -   a) erdafitinib is administered in an amount of 8 mg daily, in        particular once daily, on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <5.5 mg/dL, erdafitinib        is administered in an amount of 9 mg daily, in particular once        daily, on a continuous basis;    -   c-2) when the serum phosphate levels range from and including        5.5 mg/dL to <7 mg/dL, erdafitinib is further administered in an        amount of 8 mg daily, in particular once daily, on a continuous        basis;    -   c-3) when the serum phosphate levels are ≥7 mg/dL, the        erdafitinib treatment is interrupted temporarily until serum        phosphate levels are <5.5 mg/dL and then erdafitinib treatment        is re-started with 8 mg daily, in particular once daily, on a        continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein

-   -   a) erdafitinib is administered in an amount of 8 mg daily, in        particular once daily, on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <7 mg/dL or when the        serum phosphate levels range from and including 7 mg/dL to ≤9        mg/dL, erdafitinib is administered in an amount of 9 mg daily,        in particular once daily, on a continuous basis; and when the        serum phosphate levels range from and including 7 mg/dL to ≤9        mg/dL, concurrent treatment with a phosphate binder, such as for        example sevelamer, is optionally initiated;

c-2) when the serum phosphate levels are >9 mg/dL, the erdafitinibtreatment is interrupted temporarily until serum phosphate levels are <7mg/dL and then erdafitinib treatment is re-started with 8 mg daily, inparticular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein

-   -   a) erdafitinib is administered in an amount of 8 mg daily, in        particular once daily, on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <5.5 mg/dL and no early        onset toxicity is shown, erdafitinib is administered in an        amount of 9 mg daily, in particular once daily, on a continuous        basis;    -   c-2) when the serum phosphate levels range from and including        5.5 mg/dL to <7 mg/dL and no early onset toxicity is shown,        erdafitinib is further administered in an amount of 8 mg daily,        in particular once daily, on a continuous basis;    -   c-3) when the serum phosphate levels are ≥7 mg/dL and no early        onset toxicity is shown, the erdafitinib treatment is        interrupted temporarily until serum phosphate levels are <5.5        mg/dL and then erdafitinib treatment is re-started with 8 mg        daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 3.

The present invention concerns erdafitinib for use in the treatment ofcancer in a cancer patient, wherein

-   -   a) erdafitinib is administered in an amount of 8 mg daily, in        particular once daily, on a continuous basis;    -   b) the serum phosphate levels of the patient are measured on a        treatment day during the first cycle of erdafitinib treatment,        in particular on day 14±2 days, more in particular on day 14, of        erdafitinib administration;    -   c-1) when the serum phosphate levels are <7 mg/dL and no early        onset toxicity is shown or when the serum phosphate levels range        from and including 7 mg/dL to ≤9 mg/dL and no early onset        toxicity is shown, erdafitinib is administered in an amount of 9        mg daily, in particular once daily, on a continuous basis; and        when the serum phosphate levels range from and including 7 mg/dL        to ≤9 mg/dL, concurrent treatment with a phosphate binder, such        as for example sevelamer, is optionally initiated;    -   c-2) when the serum phosphate levels are >9 mg/dL and no early        onset toxicity is shown, the erdafitinib treatment is        interrupted temporarily until serum phosphate levels are <7        mg/dL and then erdafitinib treatment is re-started with 8 mg        daily, in particular once daily, on a continuous basis.

In an embodiment, serum phosphate levels during further erdafitinibadministration may be managed according to Table 4.

It is to be understood that the methods of treatment and uses asdescribed herein are based on phosphate levels as a pharmacodynamicmarker, but they can be modified or terminated based on toxicity. In anembodiment, treatment or uses are modified or terminated as described inTable 1.

TABLE 1 Erdafitinib dose modifications based on toxicity. Dosemodification after resolution Toxicity Grade Action of adverse event 1None Continue same dose 2 None or consider interruption If interrupted,restart at same dose or 1 dose lower, if necessary 3 Interrupt drugRestart at 1 or 2 doses lower or discontinue depending on recovery. 4Interrupt drug Discontinue

If erdafitinib is interrupted, in particular interrupted consecutivelyfor 1 week or longer due to drug-related toxicity, it may bereintroduced at either the same dose level or the first reduced doselevel following recovery from the toxicity. In an embodiment,erdafitinib dose reductions levels are as described in Table 2. A seconddose reduction may be implemented following a second occurrence ofdrug-related toxicity, in particular as described in Table 2.

TABLE 2 Erdafitinib dose reduction levels No up-titration Withup-titration Category Dose Dose Starting dose 8 mg 8 mg Up-titrationNone 9 mg 1st dose reduction 6 mg 8 mg 2nd dose reduction 5 mg 6 mg 3rddose reduction 4 mg 5 mg 4th dose reduction stop 4 mg 5th dose reductionstop

It is to be understood that, in case treatment with or administration oferdafitinib should be discontinued, for instance if erdafitinib must bewithheld for more than 28 days for a drug-related adverse event thatfails to resolve to acceptable level (≤Grade 1 or back to baseline fornon-hematologic toxicity) it is at the discretion of the physician todecide to continue treatment when the patient has been deriving benefitfrom treatment, and the physician can demonstrate that continuedtreatment with erdafitinib is in the best interest of the patient. Iferdafitinib was dose-reduced and the adverse event that was the reasonfor this dose-reduction has completely resolved, the dose may bere-escalated to the next higher level if the patient was derivingbenefit from treatment, and the physician can demonstrate that dosere-escalation of erdafitinib is in the best interest of the patient.

It is to be understood that patients with any grade of toxicity (Grade 1to 4) should be provided symptomatic treatment where applicable.

In an embodiment, if treatment with erdafitinib is interrupted asdescribed herein, and serum phosphate levels are monitored until theyreturn to the indicated levels, the assessment of serum phosphate isdone at least weekly.

In an embodiment, if treatment with erdafitinib is interrupted forhyperphosphatemia as described herein, the interruption is about 7 days,in particular is 7 days.

It is to be understood that when the serum phosphate levels are measuredas a pharmacodynamic marker for determining whether or not to up-titratethe 8 mg starting dose of erdafitinib, in particular measured on atreatment day during the first cycle of erdafitinib treatment, inparticular on day 14±2 days, more in particular on day 14, oferdafitinib administration, phosphate levels may be further monitoredduring erdafitinib treatment. In an embodiment, clinical management ofserum phosphate levels is done as represented in Table 3.

TABLE 3 Guidelines for management of serum phosphate elevation SerumPhosphate Level Erdafitinib management <5.5 mg/dL Continue erdafitinibadministration 5.5-6.9 mg/dL Continue erdafitinib administration 7.0-9.0mg/dL Withhold erdafitinib administration until serum phosphate levelreturns to <5.5 mg/dL. Re-start treatment at the same dose level. A dosereduction may be implemented if clinically indicated >9.0 mg/dL Withholderdafitinib treatment until serum phosphate level returns to <5.5 mg/dL.Re-start treatment at lower dose (e.g. first reduced dose level orsecond reduced dose level) as clinically indicated >10.0 mg/dL and/orErdafitinib should be discontinued permanently but might, significantalteration in in case of the subject having clinical benefit andre-starting baseline renal function drug is in the best interest of thesubject, be re-introduced and/or Grade 3 at lower dose. hypocalcemia

In an embodiment, clinical management of serum phosphate levels is doneas represented in Table 4.

TABLE 4 Guidelines for management of serum phosphate elevation SerumPhosphate Level Erdafitinib management <5.5 mg/dL Continue erdafitinibadministration 5.5-6.9 mg/dL Continue erdafitinib administration 7.0-9.0mg/dL Continue erdafitinib treatment. A dose reduction may beimplemented if clinically indicated. >9.0 mg/dL-10 mg/dL Withholderdafitinib treatment until serum phosphate level returns to <7.0 mg/dL(weekly testing recommended). Re-start treatment at the same dose level.A dose reduction may be implemented if clinically indicated. >10.0 mg/dLWithhold erdafitinib treatment until serum phosphate level returns to<7.0 mg/dL (weekly testing recommended). Re-start treatment at lowerdose (e.g. first reduced dose level or second reduced dose level) asclinically indicated. If hyperphosphatemia (≥10 mg/dL) for >2 weeks,erdafitinib should be discontinued permanently. Significant Erdafitinibshould be discontinued permanently but might, in alteration in case ofthe subject having clinical benefit and re-starting baseline renal drugis in the best interest of the subject, be re-introduced at function orGrade 3 lower dose. hypocalcemia

It is to be understood that for managing elevated phosphate,restrictions to daily phosphate intake may be requested.

It is to be understood that for managing elevated phosphate, patientsmay have to take concurrently a phosphate binder, such as for examplesevelamer phosphate.

Assessments of tumor responses as reported herein were performedaccording to Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1.

The present invention also concerns a package containing an erdafitinibformulation and written information, e.g. a patient leaflet, on thedosing regimens as described herein.

In an embodiment the cancers mentioned herein are cancers mediated by aFGFR kinase.

In an embodiment the cancer is bladder cancer.

In an embodiment the cancer is hepatocellular cancer.

In an embodiment the cancer is squamous cell carcinoma.

In an embodiment, the cancer is squamous NSCLC (non-small cell lungcancer), in particular squamous NSCLC (non-small cell lung carcinoma)harboring select FGFR genetic alterations, in particular the treatmentof cancer in a patient with squamous NSCLC (non-small cell lungcarcinoma) harboring select FGFR genetic alterations after relapse ofstandard of care therapy.

In an embodiment the cancer is hepatocellular cancer harboring FGF19amplification or overexpression.

In an embodiment the cancer is cholangiocarcinoma, in particularadvanced or metastatic cholangiocarcinoma.

In an embodiment, the cancer is urothelial cancer.

In an embodiment the cancer is metastatic or surgically unresectableurothelial cancer.

In an embodiment the cancer is advanced urothelial cancer with selectedFGFR gene alterations, in particular the treatment of cancer in apatient with advanced urothelial cancer with selected FGFR genealterations who has progressed on or after one prior treatment.

In an embodiment the cancer is lung cancer, in particular non small celllung cancer.

In an embodiment the cancer is selected from adenoid cystic carcinoma,mucoepidermoid carcinoma, follicular thyroid carcinoma, breastcarcinoma, Ewing sarcoma, small round cell bone tumors, synovialsarcoma, glioblastoma multiforme, pilocytic astrocytoma, lung cancer,clear cell renal cell carcinoma, bladder cancer, prostate cancer,ovarian cancer, colorectal cancer.

In an embodiment the cancer is multiple myeloma, in particular t(4;14)translocation positive multiple myeloma.

In an embodiment, the cancer is non-muscle-invasive bladder cancer, inparticular non-muscle-invasive bladder cancer with FGFR genomicalterations (e.g. translocations, fusions and/or mutations).

In an embodiment the cancer is esophageal cancer or head and neckcancer.

In an embodiment the cancer is gastric cancer.

In an embodiment, the cancers mentioned herein are cancers harboringFGFR genomic alterations (e.g. translocations, fusions and/ormutations), in particular cancers harboring FGFR genomic alterations(e.g. translocations, fusions and/or mutations) sensitive toerdafitinib, e.g. bladder cancer with FGFR genomic alterations (e.g.translocations, fusions and/or mutations), or urothelial cancer withFGFR genomic alterations (e.g. translocations, fusions and/or mutations)or metastatic or surgically unresectable urothelial cancer with FGFRgenomic alterations (e.g. translocations, fusions and/or mutations) orcholangiocarcinoma with FGFR genomic alterations (e.g. translocations,fusions and/or mutations) or advanced or metastatic cholangiocarcinomawith FGFR genomic alterations (e.g. translocations, fusions and/ormutations).

In an embodiment the cancers mentioned herein are cancers harboringalterations selected from the following fusions FGFR3:TACC3 v1;FGFR3:TACC3 v3; FGFR3:TACC3 Intron; FGFR3:BAIAP2L1; FGFR2:AFF3;FGFR2:BICC1; FGFR2:CASP7; FGFR2:CCDC6 and FGFR2:OFD1.

In an embodiment, the cancers mentioned herein are cancers with aFGFR3-TACC3 fusion or translocation, e.g. bladder cancer withFGFR3-TACC3 translocation, or urothelial cancer with FGFR3-TACC3translocation, or metastatic or surgically unresectable urothelialcancer with FGFR3-TACC3 translocation.

In an embodiment the cancers mentioned herein are cancers harboringalterations selected from the following FGFR3 gene mutations: FGFR3R248C, FGFR3 S249C, FGFR3 G370C, FGFR3 Y373C.

In an embodiment the cancers mentioned herein are bladder cancer orurothelial cancer or metastatic or surgically unresectable urothelialcancer harboring at least one of the following FGFR3 gene mutations:FGFR3 R248C, FGFR3 S249C, FGFR3 G370C, FGFR3 Y373C.

In an embodiment, the uses for or the methods of treatment of cancer ina subject in need thereof, in particular a cancer patient, as mentionedherein is the use for or the treatment of a patient with metastatic orsurgically unresectable urothelial carcinoma whose tumors harbor selectFGFR genomic alterations, who has failed during or following at leastone line of prior systemic chemotherapy, or within 12 months ofneoadjuvant or adjuvant chemotherapy, or chemo-naïve but ineligible forcisplatin.

In an embodiment, the uses for or the methods of treatment of cancer ina subject in need thereof, in particular a cancer patient, as mentionedherein, is the use for or the treatment of a patient with luminalcluster I subtype urothelial cancer.

In an embodiment erdafitinib is administered as a pharmaceuticallyacceptable salt.

In a preferred embodiment erdafitinib (base) is administered.

In an embodiment erdafitinib is administered as a pharmaceuticallyacceptable salt in an amount corresponding to 8 mg base equivalent orcorresponding to 9 mg base equivalent.

The salts can be prepared by for instance reacting erdafitinib with anappropriate acid in an appropriate solvent.

Acid addition salts may be formed with acids, both inorganic andorganic. Examples of acid addition salts include salts formed with anacid selected from the group consisting of acetic, hydrochloric,hydriodic, phosphoric, nitric, sulphuric, citric, lactic, succinic,maleic, malic, isethionic, fumaric, benzenesulphonic, toluenesulphonic,methanesulphonic (mesylate), ethanesulphonic, naphthalenesulphonic,valeric, acetic, propanoic, butanoic, malonic, glucuronic andlactobionic acids. Another group of acid addition salts includes saltsformed from acetic, adipic, ascorbic, aspartic, citric, DL-Lactic,fumaric, gluconic, glucuronic, hippuric, hydrochloric, glutamic,DL-malic, methanesulphonic, sebacic, stearic, succinic and tartaricacids.

In an embodiment, erdafitinib is administered in the form of a solvate.As used herein, the term “solvate” means a physical association oferdafitinib with one or more solvent molecules. This physicalassociation involves varying degrees of ionic and covalent bonding,including hydrogen bonding. In certain instances the solvate will becapable of isolation, for example when one or more solvent molecules areincorporated in the crystal lattice of the crystalline solid. The term“solvate” is intended to encompass both solution-phase and isolatablesolvates. Non-limiting examples of solvents that may form solvatesinclude water, isopropanol, ethanol, methanol, DMSO, ethyl acetate,acetic acid or ethanolamine and the like.

Solvates are well known in pharmaceutical chemistry. They can beimportant to the processes for the preparation of a substance (e.g. inrelation to their purification, the storage of the substance (e.g. itsstability) and the ease of handling of the substance and are oftenformed as part of the isolation or purification stages of a chemicalsynthesis. A person skilled in the art can determine by means ofstandard and long used techniques whether a hydrate or other solvate hasformed by the isolation conditions or purification conditions used toprepare a given compound. Examples of such techniques includethermogravimetric analysis (TGA), differential scanning calorimetry(DSC), X-ray crystallography (e.g. single crystal X-ray crystallographyor X-ray powder diffraction) and Solid State NMR (SS-NMR, also known asMagic Angle Spinning NMR or MAS-NMR). Such techniques are as much a partof the standard analytical toolkit of the skilled chemist as NMR, IR,HPLC and MS. Alternatively the skilled person can deliberately form asolvate using crystallisation conditions that include an amount of thesolvent required for the particular solvate. Thereafter the standardmethods described above, can be used to establish whether solvates hadformed. Also encompassed are any complexes (e.g. inclusion complexes orclathrates with compounds such as cyclodextrins, or complexes withmetals).

In an embodiment, the treatment cycle as used herein is a 28 day cycle.

In an embodiment, the patient, in particular the cancer patient, or thesubject in need of erdafitinib treatment, as used herein, is a human.

The term “about” as used herein in connection with a numerical value ismeant to have its usual meaning in the context of the numerical value.Where necessary the word “about” may be replaced by the numerical value±10%, or ±5%, or ±2%, or ±1%.

All documents cited herein are incorporated by reference in theirentirety.

EXAMPLES

Ongoing Phase 2, Multi Center, Open-Label Study (NCT02365597)

A Phase 2, multicenter, open-label study is being conducted to evaluatethe efficacy and safety of erdafitinib in subjects with metastatic orsurgically unresectable urothelial cancer harboring select FGFR geneticalterations (FGFR translocations or mutations).

The study comprises a Screening Phase (molecular screening at any timeprior to first dose and study screening within 30 days of first dose), atreatment phase, and a post-treatment follow-up phase. The treatmentphase comprises the period from first dose until the end-of-treatmentvisit. The follow-up phase will extend until the subject has died,withdraws consent, is lost to follow-up, or the end of study, whichevercomes first.

Study treatment is administered on 28-day cycles. Prior to interimanalysis 1, there were 2 treatment regimens. Patients were randomized1:1 to 28 day cycles to the following 2 regimens until a regimen wasselected for further study: Regimen 1 (10 mg once daily intermittent (7days on/7 days); Regimen 2 (6 mg once daily continuous). Followinginterim analysis 1 and based on the results of pharmacokinetic andpharmacodynamic modeling linking erdafitinib dose regimen and serumphosphate levels, the protocol was amended to increase the starting doseto 8 mg/day continuous dosing (Regimen 3) with an up-titration to 9mg/day at day 14 in patients who did not reach target serum phosphatelevels at this timepoint (patients with serum phosphate levels <5.5mg/dL) and in whom no treatment-related adverse events were observed).Dose reductions based on observed toxicity (treatment-related adverseevents (TRAEs)) was foreseen in the protocol.

See FIG. 1 for the Phase 2 study scheme.

Patients

Included patients were adults with measurable urothelial cancer perResponse Evaluation Criteria in Solid Tumors version 1.1.

Patients were required to have at least 1 FGFR2/FGFR3 mutation or fusionper central lab testing of RNA from formalin-fixed, paraffin-embeddedtumor samples, using a custom assay.

Patients had progressed during or following at least 1 line of priorsystemic chemotherapy or less than 12 months of neoadjuvant or adjuvantchemotherapy.

Chemotherapy-naïve patients who were ineligible for cisplatin based onprotocol criteria were allowed. Ineligibility for cisplatin was based onimpaired renal function, defined as 1) glomerular filtration rate <60mL/min/1.73 m² by 24-hour urine measurement; 2) calculated byCockcroft-Gault; or 3) grade 2 or higher peripheral neuropathy (CommonTerminology Criteria for Adverse Events [CTCAE] version 4.0 (NationalCancer Institute. CTCAE v4.0. NCI, NIH, DHHS. May 29, 2009. NIHpublication #09-7473: 2009).

Eastern Cooperative Oncology Group (ECOG) performance status 0-2 wasrequired.

There was no limit on the number of prior lines of treatment.

Prior immunotherapy (eg, treatment with a PD-L1/PD-1 inhibitor) wasallowed.

Patients were required to have adequate bone marrow, liver and renal(creatinine clearance ≥40 mL/min) function.

Patients with phosphate levels persistently above the upper limit ofnormal despite medical management, uncontrolled cardiovascular disease,brain metastases, known hepatitis B or

C, or known HIV were excluded.

End Points

The primary end point of this ongoing study is Objective Response Rateto the selected regimen (Regimen 3).

Secondary end points include progression-free survival (PFS), durationof response (DoR), Overall Survival, safety, predictive biomarkerevaluation, and pharmacokinetics.

Assessments

Patients were assessed for efficacy using radiographic imaging performedwithin 30 days of screening, once every 6 weeks for the first 3 months,once every 12 weeks for the next 9 months, then once every 4 to 6 monthsuntil disease progression.

Tumor responses were assessed by investigators according to RECISTversion 1.1 (Eisenhauer E A et al., Eur J Cancer, 2009, 45(2), 228-247).

Safety was assessed continuously by the investigator and based onmedical review of AE reports and the results of vital sign measurements,physical examinations, clinical laboratory tests, ECOG performancestatus, and other safety evaluations.

Results

Baseline characteristics and efficacy data are presented for 170patients enrolled between May 7, 2015, and Jun. 10, 2017, and consideredresponse evaluable according to RECIST 1.1 (Table 5).

Safety data are presented for the safety population (N=207, enrolledbetween May 7, 2015, and Dec. 5, 2017), defined as patients who receivedat least 1 dose of study treatment. As of Dec. 5, 2017, the mediantreatment duration was 4.2 months, and patients had received a median of5 cycles of erdafitinib.

During the screening phase, 21% of patients had an FGFR mutation orfusion meeting inclusion criteria.

Across dose regimens, 89% had progressed following at least 1 line ofprior treatment with systemic chemotherapy.

TABLE 5 Baseline Characteristics^(a) Regimen 1 Regimen 2 Regimen 3 10 mg6 mg 8 mg intermittent dose continuous dose continuous dose (n = 33) (n= 78) (n = 59) Age, median (range) 68 (53-88) 65 (42-88) 67 (36-87) ECOGperformance status  0 11 (33) 22 (28) 35 (59)  1 15 (46) 41 (53) 20 (34) 2 7 (21) 15 (19) 4 (7) Pretreatment Chemo-refractory^(b) 29 (88) 73(94) 50 (85) Chemo-naïve^(c) 4 (12) 5 (6) 9 (15) Prior immunotherapy 3(9) 8 (10) 11 (19) Number of lines of prior treatment  0 3 (9) 6 (8) 8(14)  1 14 (42) 34 (44) 27 (46)  2 11 (33) 25 (32) 18 (31)  3 4 (12) 11(14) 5 (8) >3 1 (3) 2 (3) 1 (2) Visceral metastases Present 24 (73) 60(77) 45 (76) Absent 9 (27) 18 (23) 14 (24) Creatinine clearance rate40-59 mL/min 12 (36) 40 (51) 32 (54)  ≥60 mL/min 21 (64) 38 (49) 27 (46)Any FGFR alteration^(d) 33 (100) 78 (100) 59 (100) FGFR2/3 fusion^(d) 6(18) 15 (21) 20 (34) FGFR3 mutation^(d) 30 (91) 66 (85) 39 (66) BothFGFR mutation and 3 (9) 4 (5) 0 fusion All values are n (%) unlessnoted. ^(a)Data from all patients as of Jun. 10, 2017, data cutoff (n =170). ^(b)Chemotherapy-refractory patients were those who had progressedduring or following ≥1 line of prior systemic chemotherapy or within 12months of adjuvant or neoadjuvant chemotherapy. ^(c)Chemotherapy-naïvepatients were those who were ineligible for cisplatin. Ineligibility forcisplatin was based on impaired renal function defined as 1) glomerularfiltration rate <60 mL/min/1.73 m2 by 24-hour urine measurement; 2)calculated by Cockcroft-Gault; or 3) grade 2 or higher peripheralneuropathy (CTCAE version 4.0). ^(d)Patients could have more than FGFRalteration.

Across all dose regimens, the confirmed Objective Response Rate was 35%(95% CI, 28%-43%), with the highest rate among patients who were treatedwith 8 mg/d continuous erdafitinib in Regimen 3 (Table 6). The confirmeddisease control rate was 76% among all patients. The majority ofpatients treated with 8 mg/d continuous erdafitinib had reduction intumor burden (44/59 [75%] had reduction in the sum of target lesiondiameters; FIG. 2). Median Progression Free Survival was 5.1 months andwas most prolonged among patients who were treated with 8 mg/dcontinuous erdafitinib in Regimen 3 (Table 6). Median duration ofresponse in the 8 mg/d continuous erdafitinib group (Regimen 3) was 5.4months, and many responses are ongoing (Table 6).

TABLE 6 Antitumor Activity of 3 Dose Regimens of Erdafitiniba Regimen 1Regimen 2 Regimen 3 10 mg 6 mg 8 mg intermittent dose continuous dosecontinuous dose (n = 33) (n = 78) (n = 59) ORR, confirmed, n (%) 8 (24)27 (35) 25 (42) Complete response 2 (6) 2 (3) 3 (5) Partial response 6(18) 25 (32) 22 (37) Stable disease 16 (49) 30 (39) 23 (39) P value ofORR compared 0.354  0.082 — with ORR in Regimen 3 Disease control rate,24 (73) 57 (73) 48 (81) confirmed, n (%) Duration of response, 12.6 4.95.4 median, months Follow-up for survival, 18.4 15.5  8.8 median, monthsProgression-free survival, 4.0 5.1 5.6 median, months ^(a)Data from allpatients as of Jun. 10, 2017, data cutoff (n = 170). ORR, confirmed =Confirmed Objective Response Rate = Confirmed Complete Response +Confirmed Partial Response. Disease Control Rate, confirmed = ConfirmedComplete Response + Confirmed Partial Response + Stable disease

Time to Response

The median time to response in the subset of 59 patients on Regimen 3was 1.41 months, with a range of 1.1 to 5.5 months.

Across all dose regimens, 94% (n=195) of patients reported TRAEs; mostof these were grade 1 or 2 (Table 7). 33% (n=69) of patients reportedgrade 3 TRAEs, 0.5% (n=1) of patients reported grade 4 TRAEs, and therewere no treatment-related deaths.

AEs were manageable.

Prophylaxis recommendations for key AEs related to treatment witherdafitinib:

-   -   To reduce risk of hyperphosphatemia, a low-phosphate diet was        recommended for all patients (600-800 mg of dietary phosphate        intake per day).    -   To reduce risk of skin effects, the application of alcohol-free,        emollient moisturizing cream and avoidance of unnecessary        exposure to sunlight, soap, perfumed products, and hot baths was        recommended.    -   To reduce risk of nail effects, it was recommended that patients        keep their fingers and toes cleaned and nails trimmed.

Management

-   -   Hyperphosphatemia (>5.5 mg/dL) was managed with a        phosphate-binding agent when medically warranted.    -   Dry skin was managed with additional topical ointments such as        ammonium lactate, salicylic acid, or zinc oxide creams.    -   Nail effects were managed with topical nail strengthener;        antibiotics or silver nitrate were applied in severe cases.

TRAEs associated with the class of FGFR inhibitors were typically grade1 or 2; across all dose regimens, 2 patients reported retinopathy (grade2 [n=1] and grade 3 [n=1]). Across all dose regimens, 22 (11%) patientsdiscontinued as the result of TRAEs. The most common TRAEs leading totreatment discontinuation were asthenia, dry mouth, and palmar-plantarerythrodysaesthesia syndrome.

TABLE 7 TRAEs Reported in ≥10% of Patients in Regimen 3^(a) Regimen 1Regimen 2 Regimen 3 10 mg intermittent 6 mg continuous 8 mg continuousdose dose dose (n = 33) (n = 78) (n = 96) Any grade Grade ≥3 Any gradeGrade ≥3 Any grade Grade ≥3 AEs, n (%) Hyperphosphatemia 15 (46) 0 48(62) 0 66 (69) 2 (2) Stomatitis 16 (49) 1 (3) 32 (41) 7 (9) 45 (47) 8(8) Diarrhea 13 (39) 1 (3) 34 (44) 0 40 (42) 3 (3) Dry mouth 14 (42) 031 (40) 2 (3) 40 (42) 0 Dysgeusia 10 (30) 0 10 (13) 0 32 (33) 1 (1) Dryskin 7 (21) 0 17 (22) 0 26 (27) 0 Decreased appetite 7 (21) 0 18 (23) 2(3) 23 (24) 0 Alopecia 3 (9) 0 7 (9) 0 22 (23) 0 Fatigue 4 (12) 0 14(18) 1 (1) 19 (20) 1 (1) Dry eye 2 (6) 0 2 (3) 1 (1) 17 (18) 0 Visionblurred 4 (12) 0 5 (6) 1 (1) 15 (16) 0 Palmar-plantar 2 (6) 0 12 (15) 015 (16) 4 (4) erythrodysaesthesia syndrome Paronychia 2 (6) 0 11 (14) 014 (15) 3 (3) Asthenia 6 (18) 2 (6) 12 (15) 4 (5) 13 (14) 3 (3) Naildystrophy 2 (6) 0 7 (9) 0 12 (13) 3 (3) Lacrimation increased 4 (12) 011 (14) 0 8 (8) 0 Onycholysis 5 (15) 0 13 (17) 5 (6) 10 (10) 1 (1) FGFRinhibitor class effects (summed terms Eye AEs 14 (42) 1 (3) 27 (35) 2(3) 55 (57) 5 (5) Skin and 14 (42) 1 (3) 47 (60) 5 (6) 63 (66) 13 (14)subcutaneous AEs ^(a)Data from all patients as of Dec. 5, 2017, datacutoff (N = 207).

1-15. (canceled)
 16. A method comprising: a) administering to a subjectin need thereof 8 mg of erdafitinib daily on a continuous basis; b)measuring the serum phosphate levels of the patient on a treatment dayduring the first cycle of erdafitinib treatment; c-1) when the serumphosphate levels are <7 mg/dL or when the serum phosphate levels rangefrom and including 7 mg/dL to ≤9 mg/dL, erdafitinib is administered inan amount of 9 mg daily on a continuous basis; and when the serumphosphate levels range from and including 7 mg/dL to ≤9 mg/dL,concurrent treatment with a phosphate binder is optionally initiated; orc-2) when the serum phosphate levels are >9 mg/dL, the erdafitinibtreatment is interrupted temporarily.
 17. The method according to claim16, wherein, when the serum phosphate levels are >9 mg/dL, theerdafitinib treatment is interrupted temporarily until serum phosphatelevels are <7 mg/dL.
 18. The method according to claim 17, wherein, whenthe serum phosphate levels are >9 mg/dL, the erdafitinib treatment isinterrupted temporarily until serum phosphate levels are <7 mg/dL andthen erdafitinib treatment is re-started with 8 mg daily on a continuousbasis.
 19. The method according to claim 16, wherein, when the serumphosphate levels are ≥10 mg/dL for >2 weeks, the erdafitinib treatmentis interrupted permanently.
 20. The method according to claim 16,wherein 8 mg of erdafitinib is administered once daily.
 21. The methodaccording to claim 16 wherein 9 mg of erdafitinib is administered oncedaily.
 22. The method according to claim 16, wherein the serum phosphatelevels of the patient are measured on day 14±2 days during the firstcycle of erdafitinib treatment.
 23. The method according to claim 22,wherein the serum phosphate levels of the patient are measured on day 14during the first cycle of erdafitinib treatment.
 24. The methodaccording to claim 16, wherein concurrent treatment with a phosphatebinder is initiated.
 25. The method according to claim 16, wherein thesubject has a cancer harboring FGFR genomic alterations.
 26. The methodaccording to claim 25, wherein the alterations are selected from thefollowing fusions FGFR3:TACC3 v1; FGFR3:TACC3 v3; FGFR3:TACC3 Intron;FGFR3:BAIAP2L1; FGFR2:AFF3; FGFR2:BICC1; FGFR2:CASP7; FGFR2:CCDC6 andFGFR2:OFD1.
 27. The method according to claim 25 wherein the alterationis a FGFR3-TACC3 fusion.
 28. The method according to claim 25, whereinthe cancer is bladder cancer with FGFR3-TACC3 translocation, orurothelial cancer with FGFR3-TACC3 translocation, or metastatic orsurgically unresectable urothelial cancer with FGFR3-TACC3translocation.
 29. The method according to claim 25, wherein thealterations are selected from the following FGFR3 gene mutations: FGFR3R248C, FGFR3 S249C, FGFR3 G370C, FGFR3 Y373C.
 30. The method accordingto claim 25, wherein the cancer is bladder cancer or urothelial canceror metastatic or surgically unresectable urothelial cancer harboring atleast one of the following FGFR3 gene mutations: FGFR3 R248C, FGFR3S249C, FGFR3 G370C, FGFR3 Y373C.
 31. The method according to claim 16,wherein 8 mg of erdafitinib is to be administered as two formulations.32. The method according to claim 31, wherein the two formulations aretwo tablets, each comprising 4 mg of erdafitinib.
 33. The methodaccording to claim 16, wherein 9 mg of erdafitinib is to be administeredas three formulations.
 34. The method according to claim 33, wherein thethree formulations are three tablets, each comprising 3 mg oferdafitinib.